Center of Excellence in Advanced Pharmaceutical Technologies

Description du projet

La République tchèque établit le Pharma Centre of Excellence in Advanced Technology

Les acides nucléiques, notamment l’ADN et l’ARN, ont montré un potentiel intéressant dans le traitement de nombreuses maladies, sans parler de leur utilisation dans les vaccins, comme lors de la pandémie de COVID-19. Le transport dirigé vers des tissus et des cellules spécifiques représente toujours un défi. La faculté de pharmacie de l’université Masaryk, en République tchèque, est très bien placée pour le relever. Le projet ExcellPharmTech, financé par l’UE, recrutera une chaire de l’Espace européen de la recherche pour établir le Pharma Centre of Excellence in Advanced Technology, intensifier la recherche et le développement pour permettre l’administration ciblée d’acides nucléiques aux cellules cibles et développer des partenariats stratégiques pour accélérer la mise en œuvre de médicaments avancés dans le cadre clinique.

Objectif

Masaryk University (MU) is the second-largest university in the Czech Republic located in Brno. Thanks to the ESIF funding, MU was able to acquire top research infrastructure attracting talented researchers who gradually built the position of the MU as the top regional hub for education, research, and innovation.
To further exploit this potential, the management structures and processes of the university must thoroughly implement the European Research Area (ERA) Priorities. As an outstanding researcher/innovator can have a decisive and positive impact on the culture and performance of any institution, MU will recruit a world-class research manager as an ERA Chair for its newly-established Faculty of Pharmacy.
The Faculty of Pharmacy (MUNI Pharm) is, besides others, focused on the development of advanced drug formulations and molecular biology techniques. The ERA Chair will intensify the research and development of advanced drug formulation and nanotechnologies to open new opportunities to intensify MUNI Pharm research capacities in the field of pharmacy and develop strategic partnerships with the application sphere and public sector for faster translation of the advanced drugs into clinics.
The recruitment of leading scientist will enforce the connection of the MUNI Pharm to research structures of MU, and the ERA Chair will make a bridge in the formation of unique education and research facility at one place titled MUNI BioPharma Hub, supported from National Recovery Plan (part of RRF – Recovery and Resilience Facility, NextGeneration EU).
To solve the targeted delivery and transportation of nucleic acids into target cell environment, the MUNI Pharm will establish an interdisciplinary center of excellence (Pharma Center of Excellence in Advanced Technology) with prof. David Oupický as its leader. The creation of an international ERA Chair team will ensure a successful establishment of the center combining excellent research, high level education and top innovations.